Showing results (161-170 of 180) with videos related to
Sort By:
Pageof 18
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2013
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesisChristoph J Heuck, Jayesh Mehta, Tushar Bhagat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern eraAndrew M Evens, Kevin A David, Irene Helenowski, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.Blood Cancer Journal|February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.International Journal of Cancer|June 8, 2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource SettingsNeerja Bhatla, MaryLuz Rol, Seema Singhal, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.Neuro-Oncology|May 5, 2017
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendrogliomaAlissa A Thomas, Lauren E Abrey, Robert Terziev, et al.Pageof 18